logo
Plus   Neg
Share
Email

Icon Bioscience Reports Phase 3 Data For IBI-10090 - Quick Facts

Icon Bioscience Inc. announced that Phase 3 data showed significantly positive outcomes for IBI-10090 compared to placebo in treating inflammation associated with cataract surgery. The company reported that the ensuing analysis of data showed IBI-10090 - with regard to both primary and secondary study endpoints - to be safe as well as highly effective.

The Phase 3 study of IBI-10090 was a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial involving 394 patients.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Biopharmaceutical company Bristol-Myers Squibb Co. on Thursday reported a loss for the second quarter, compared to a profit last year, hurt primarily by hefty amortization expenses. However, adjusted earnings per share and quarterly revenues topped analysts' expectations. Looking ahead, the company raised its adjusted earnings and revenue outlook for the full-year 2020. Shares of Deutsche Lufthansa AG were losing around 3 percent in German trading after the airline reported Thursday a loss in its second quarter, compared to prior year's profit with sharply lower revenues with collapse in demand for air travel due to the Corona pandemic. Going ahead, the airline projects a clearly negative adjusted EBIT in the second half of 2020 and a further significant decline Former Google engineer Anthony Levandowski was sentenced by a U.S. judge to eighteen months in prison for stealing trade secrets from Google's self-driving car unit before he defected to Uber's rival unit. Levandowski admitted that from 2009 to 2016, he worked in Google's self-driving car program, known then as Project Chauffer.
Follow RTT